Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Gains from Investment Securities (2016 - 2026)

Corvus Pharmaceuticals' Gains from Investment Securities history spans 12 years, with the latest figure at $661334.0 for Q1 2026.

  • Quarterly Gains from Investment Securities fell 94.29% to $661334.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $661334.0 through Mar 2026, down 94.29% year-over-year, with the annual reading at $14.0 million for FY2025, 17.54% up from the prior year.
  • Gains from Investment Securities came in at $661334.0 for Q1 2026, down from $5.6 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $11.6 million in Q1 2025 to a low of -$2.0 million in Q2 2025.
  • The 5-year median for Gains from Investment Securities is $373705.0 (2023), against an average of $1.3 million.
  • The largest YoY upside for Gains from Investment Securities was 40163.25% in 2025 against a maximum downside of 483.24% in 2025.
  • Corvus Pharmaceuticals' Gains from Investment Securities stood at -$985000.0 in 2022, then fell by 4.37% to -$1.0 million in 2023, then soared by 328.31% to $2.3 million in 2024, then soared by 138.45% to $5.6 million in 2025, then plummeted by 88.18% to $661334.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Gains from Investment Securities are $661334.0 (Q1 2026), $5.6 million (Q3 2025), and -$2.0 million (Q2 2025).